Evidence map›Paper›PMID 27098957›Full record

ArticleJournal of clinical microbiology2016

Towards Development of Improved Serodiagnostics for Tularemia by Use of Francisella tularensis Proteome Microarrays.

Rie Nakajima, Raquel Escudero, Douglas M Molina, Manuela Rodríguez-Vargas, Arlo Randall, Algis Jasinskas, Jozelyn Pablo, Philip L Felgner, David P AuCoin, Pedro Anda and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of clinical microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Frontiers in cellular and infection microbiology · 2020
    Review
  4. Article
  5. Identification ofClinical proteomics · 2018
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Rie NakajimaDivision of Infectious Diseases, School of Medicine, University of California, Irvine, Irvine, California, USA.
Raquel EscuderoLaboratorio de Espiroquetas y Patógenos Especiales, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain.
Douglas M MolinaAntigen Discovery, Inc., Irvine, California, USA.
Manuela Rodríguez-VargasLaboratorio de Espiroquetas y Patógenos Especiales, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain.
Arlo RandallAntigen Discovery, Inc., Irvine, California, USA.
Algis JasinskasDivision of Infectious Diseases, School of Medicine, University of California, Irvine, Irvine, California, USA.
Jozelyn PabloAntigen Discovery, Inc., Irvine, California, USA.
Philip L FelgnerDivision of Infectious Diseases, School of Medicine, University of California, Irvine, Irvine, California, USA.
David P AuCoinDepartment of Microbiology and Immunology, School of Medicine, University of Nevada, Reno, Nevada, USA.
Pedro AndaÁrea de Orientación Diagnóstica, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain.
D Huw DaviesDivision of Infectious Diseases, School of Medicine, University of California, Irvine, Irvine, California, USA ddavies@uci.edu.
Antigen Discovery (United States) · USUniversity of California, Irvine · USInstituto de Salud Carlos III · ESCentro Nacional de Microbiologia · ESUniversity of Nevada, Reno · US

Funding

Vaccines and Diagnostics TrialsU54AI065359 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BARBOUR, ALAN G. · 2005 to 2013
$88.8M
University of California Health Participation in the National COVID Cohort Collaborative (N3C)UL1TR001414 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI COOPER, DAN M, VILAIN, ERIC J. · 2015 to 2023
$35.1M
Multiplex Serodiagnostic Protein MicroarrayU01AI078213 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI FELGNER, PHILIP LOUIS · 2008 to 2012
$3.7M
NCATS NIH HHS UL1 TR001414NIAID NIH HHS U01 AI078213NIAID NIH HHS U54 AI065359
6 · The paper itself

Abstract

Tularemia in humans is caused mainly by two subspecies of the Gram-negative facultative anaerobe Francisella tularensis: F. tularensis subsp. tularensis (type A) and F. tularensis subsp. holarctica (type B). The current serological test for tularemia is based on agglutination of whole organisms, and the reactive antigens are not well understood. Previously, we profiled the antibody responses in type A and B tularemia cases in the United States using a proteome microarray of 1,741 different proteins derived from the type A strain Schu S4. Fifteen dominant antigens able to detect antibodies to both types of infection were identified, although these were not validated in a different immunoassay format. Since type A and B subspecies are closely related, we hypothesized that Schu S4 antigens would also have utility for diagnosing type B tularemia caused by strains from other geographic locations. To test this, we probed the Schu S4 array with sera from 241 type B tularemia cases in Spain. Despite there being no type A strains in Spain, we confirmed the responses against some of the same potential serodiagnostic antigens reported previously, as well as determined the responses against additional potential serodiagnostic antigens. Five potential serodiagnostic antigens were evaluated on immunostrips, and two of these (FTT1696/GroEL and FTT0975/conserved hypothetical protein) discriminated between the Spanish tularemia cases and healthy controls. We conclude that antigens from the type A strain Schu S4 are suitable for detection of antibodies from patients with type B F. tularensis infections and that these can be used for the diagnosis of tularemia in a deployable format, such as the immunostrip.

Indexed as

Microarray AnalysisAdultAntibodies, BacterialAntigens, BacterialFrancisella tularensisHumansProteomeSerologic TestsSpainTularemiaUnited StatesAntibodies, BacterialAntigens, BacterialProteome

Identifiers

PMID27098957
PMCPMC4922089
OpenAlexW2341847144

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.